UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance
Authors
Keywords
-
Journal
CELL DEATH AND DIFFERENTIATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-10
DOI
10.1038/s41418-020-00616-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85
- (2018) Shuangbing Xu et al. CANCER LETTERS
- β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer
- (2018) Jia Ma et al. CELL DEATH AND DIFFERENTIATION
- Ubiquitin-conjugating enzyme UBE2O regulates cellular clock function by promoting the degradation of the transcription factor BMAL1
- (2018) Suping Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- S6K1 phosphorylation-dependent degradation of Mxi1 by β-Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer
- (2018) Yumei Huang et al. Theranostics
- CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer
- (2018) Jie Xie et al. Theranostics
- Principles of Ubiquitin-Dependent Signaling
- (2018) Eugene Oh et al. Annual Review of Cell and Developmental Biology
- Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset
- (2018) Kifayat Ullah et al. FEBS Journal
- The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis
- (2017) Yujia Xu et al. Journal of Hematology & Oncology
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells
- (2017) Q Wang et al. ONCOGENE
- UBE2O remodels the proteome during terminal erythroid differentiation
- (2017) Anthony T. Nguyen et al. SCIENCE
- UBE2O is a quality control factor for orphans of multiprotein complexes
- (2017) Kota Yanagitani et al. SCIENCE
- Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers
- (2016) Petra Schwertman et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Proteomic Analysis of the Human Cyclin-dependent Kinase Family Reveals a Novel CDK5 Complex Involved in Cell Growth and Migration
- (2014) Shuangbing Xu et al. MOLECULAR & CELLULAR PROTEOMICS
- Autodeubiquitination Protects the Tumor Suppressor BAP1 from Cytoplasmic Sequestration Mediated by the Atypical Ubiquitin Ligase UBE2O
- (2014) Nazar Mashtalir et al. MOLECULAR CELL
- Regulation of WASH-Dependent Actin Polymerization and Protein Trafficking by Ubiquitination
- (2013) Yi-Heng Hao et al. CELL
- UBE2O negatively regulates TRAF6-mediated NF-κB activation by inhibiting TRAF6 polyubiquitination
- (2013) Xiaofei Zhang et al. CELL RESEARCH
- Fine-tuning BMP7 signalling in adipogenesis by UBE2O/E2-230K-mediated monoubiquitination of SMAD6
- (2013) Xiaofei Zhang et al. EMBO JOURNAL
- MAX and MYC: A Heritable Breakup
- (2012) A. Cascon et al. CANCER RESEARCH
- hSSB1 regulates both the stability and the transcriptional activity of p53
- (2012) Shuangbing Xu et al. CELL RESEARCH
- Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair
- (2010) Eva Petermann et al. MOLECULAR CELL
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started